CTLA4 and cancer: Although remarkable progress has been made in cancer treatment through the blockade of CTLA-4 or PD-1 signaling using monoclonal antibodies (mAbs), most patients do not respond to immunotherapy because of primary or acquired drug resistance (7, 8).